欢迎来到CSNpharm！产品仅用于科研！

400-920-2911 sales@csnpharm.cn

NEW 新产品
0

c-Met/HGFR

c-Met/HGFR

货号 产品名 CAS号 信息
CSN28428 Zanzalintinib 2367004-54-2 XL-092 is an ATP-competitive inhibitor of multiple receptor tyrosine kinases including MET, VEGFR2, AXL and MER, with IC50 values of 15, 1.6, 3.4, and 7.2 nM, respectively, in cell-based assays.
CSN28428 Zanzalintinib 2367004-54-2 XL-092 is an ATP-competitive inhibitor of multiple receptor tyrosine kinases including MET, VEGFR2, AXL and MER, with IC50 values of 15, 1.6, 3.4, and 7.2 nM, respectively, in cell-based assays.
CSN17399 Tyrosine kinase inhibitor 1021950-26-4 Tyrosine kinase inhibitor is a drug used for advanced renal cell carcinoma.
CSN12917 Tivantinib 905854-02-6 Tivantinib is an non-ATP-competitive c-Met inhibitor with Ki of 0.355 μM with little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4.
CSN12733 SU11274 658084-23-2 SU11274 is a selective Met inhibitor with IC50 of 10 nM, no effects on PGDFRβ, EGFR or Tie2.
CSN16106 SGX-523 1022150-57-7 SGX-523 is a potent and selective c-Met inhibitor with IC50 of 4 nM.
CSN17517 SCR-1481B1 1174161-86-4 SCR-1481B1 is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor.
CSN17684 Savolitinib 1313725-88-0 Savolitinib is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase (IC50= 5 nM) with potential antineoplastic activity.
CSN20348 SAR125844 1116743-46-4 SAR125844 is a potent and highly selective c-Met inhibitor with potential antineoplastic activity.
CSN19153 S49076 1265965-22-7 S49076 is a potent inhibitor of MET, AXL/MER, and FGFRs.
CSN12934 PHA-665752 477575-56-7 PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM.
CSN26511 PF-04217903 phenolsulfonate 1159490-85-3 PF-04217903 phenolsulfonate is a potent ATP-competitive c-Met kinase inhibitor with Ki of 4.8 nM for human c-Met. PF-04217903 phenolsulfonate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties[1][2].
CSN18635 PF-04217903 methanesulfonate 956906-93-7 PF-04217903 Methanesulfonate is a highlu selective c-Met inhibitor with IC50 of 4.8 nM.
CSN16129 PF-04217903 956905-27-4 PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant).
CSN17159 NVP-BVU972 1185763-69-2 NVP-BVU972 is a potent and selective c-Met inhibitor with IC50 of 14 nM with antitumor effects.
CSN23572 Norcantharidin 29745-04-8 Norcantharidin is a potential antitumor agent.
CSN23685 Ningetinib Tosylate 1394820-77-9 Ningetinib tosylate is an inhibitor of tyrosine kinase inhibitor (TKI) and the IC50 for c-Met, VEGFR2 and Axl are 6.7 nM, 1.9 nM and <1.0 nM respectively.
CSN17658 MK-8033 hydrochloride 1283000-43-0 MK8033 HCl is a specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.
CSN13613 MK-8033 1001917-37-8 MK-8033 is a specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.
CSN16566 MK-2461 917879-39-1 MK-2461 is a potent and multi-targeted inhibitor for c-Met with IC50 of 0.4-2.5 nM, also inhibits FGFR1/2/3, KDR, TrkA/B, and Flt4 with IC50 of 65/39/50 nM, 44 nM, 46/61 nM, and 78 nM respectively.
CSN26620 MET kinase-IN-2 2101241-90-9 MET kinase-IN-2 is a potent, selective, orally bioavailable MET kinase inhibitor with an IC50 of 7.4 nM. MET kinase-IN-2 has antitumor activity[1].
CSN13734 Merestinib 1206799-15-6 LY2801653 is a potent and orally bioavailable inhibitor of c-MET kinase with Ki of 2 nM.
CSN17560 Merestinib dihydrochloride 1206801-37-7 LY2801653 2HCl is a potent, orally bioavailable, small-molecule inhibitor of c-MET kinase (Ki= 2 nM).
CSN22436 JNJ-38877618 943540-74-7 JNJ-38877618 is a potent, highly selective, orally bioavailable Met kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met, respectively.
CSN12936 JNJ-38877605 943540-75-8 JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM.
CSN15776 Capmatinib 1029712-80-8 INCB28060 is a potent and selective c-MET kinase inhibitor. INCB28060 inhibits c-MET kinase activity with an average IC50 of 0.13 nM.
CSN19988 Herbacetin 527-95-7 Herbacetin, a natural product isolated and purified from the herbs of Equisetum hyemale L. It was found to efficiently block the enzymatic activity of SARS-CoV 3CLpro.
CSN15829 Golvatinib 928037-13-2 Golvatinib is a dual c-Met and VEGFR-2 inhibitor with IC50 of 14 nM and 16 nM.
CSN24153 Glumetinib 1642581-63-2 Glumetinib is a novel, potent and highly selective inhibitor of c-Met.
CSN17479 Glesatinib hydrochloride 1123838-51-6 Glesatinib HCl is an inhibitor of the MET and Axl receptor tyrosine kinase pathways, which drive tumour growth when altered.
CSN12685 Foretinib 849217-64-7 Foretinib is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM in cell-free assays. Foretinib is less potent against Ron, Flt-1/3/4, Kit, PDGFRα/β and Tie-2, and with little activity to FGFR1 and EGFR.
CSN26544 EGFR-IN-8 2407957-87-1 EGFR-IN-8 is a dual EGFR and c-Met inhibitor, compound 48. EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC[1].
CSN24316 N-((S)-1-(((2S,3S)-1-((6-Amino-6-oxohexyl)amino)-3-methyl-1-oxopentan-2-yl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)hexanamide acetate 2453297-24-8 Dihexa is a blood-brain barrier-permeable angiotensin IV analog which exhibits high affinity to HGF with Kd value of 65pM and induces c-Met phosphorylation in the presence of subthreshold concentrations of HGF and augment HGF-dependent cell scattering.
CSN24802 BPR1K871   2443767-35-7 DBPR114 is a potent multi-kinase inhibitor with potent activities against more than 57 oncogenic kinases, including Aurora-A, FLT3, CSF1R, MET, etc. DBPR114 exhibited favorable PK profiles: a long half-life (t1/2 = 23.5 h), moderate clearance and high volume of distribution. Also DBPR114 can effectively inhibit the growth of human acute myeloid leukemia MOLM-13 and MV4-11, MIA PaCa-2, Hep3B, MKN45, Colo205, and NTUB1 solid tumor xenografts in vivo without causing significant body weight loss.
CSN15710 Cabozantinib 849217-68-1 Cabozantinib is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively.
CSN25585 SYN1143 913376-84-8 c-Met/RON Dual Kinase Inhibitor is a potent inhibitor against the kinase activities of HGF receptor c-Met and MSP (Macrophage Stimulating Protein) receptor RON with IC50 of 4 and 9 nM, respectively, and it is reported to inhibit NIH3T3 TRP-Met and U-87 tumor growth in mice in vivo in a dose-dependent manner.
CSN22378 c-Met-IN-2 1635406-73-3 c-Met-IN-2 is a potent, selective and orally available c-Met inhibitor, with an IC50 of 0.6 nM, with antitumor activity.
CSN16262 c-Met inhibitor 1 1357072-61-7 c-Met Inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.
CSN23729 Bozitinib 1440964-89-5 Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily[1].
CSN16525 BMS-794833 1174046-72-0 BMS-794833 is a potent ATP competitive inhibitor of Met and VEGFR2 with IC50 of 1.7 and 15 nM.
CSN13471 BMS 777607 1025720-94-8 BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, being 40-fold selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases.
CSN15865 BMS-754807 1001350-96-4 BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc.
CSN25296 BAY-474 1033767-86-0 BAY 474 is a tyrosine-protein kinase c-Met inhibitor and a structural genomics consortium (SGC) epigenetics probe.
CSN17199 AMG-458 913376-83-7 AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.
CSN17516 AMG-337 1173699-31-4 AMG-337 is a potent, highly selective and ATP-competitive MET kinase inhibitor with an IC50 of < 5nM in enzymatic assays.
CSN16548 AMG-208 1002304-34-8 AMG-208 is a potent small molecular c-Met inhibitor with an IC50 of 9.3 nM.
CSN16259 Altiratinib 1345847-93-9 Altiratinib is a c-MET/TIE-2/VEGFR inhibitor which effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro.
<< PREV 1 2 NEXT >>
dandb BBB norton fedex dhl ups 顺丰

csnpharm版权所有2023，产品仅用于科研！

联系
我们